Nuvectis Pharma, Inc.
NVCTNuvectis Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative precision medicines for serious unmet needs in oncology.
Earnings
Next report
Aug 4, 2026 (In 6 days)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Nuvectis Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative precision medicines for serious unmet needs in oncology. The company focuses on small molecule drug candidates that target specific cancer-promoting factors, utilizing a data-driven approach to navigate the clinical and regulatory landscape. Its primary value proposition lies in advancing novel therapies that inhibit key oncogenic pathways, such as SRC and YES1, to treat solid tumors.
Nuvectis is a clinical-stage developer focused on a novel 'closed conformation' mechanism for SRC inhibition, aiming to differentiate from existing multi-kinase inhibitors.
Questions, answered.
- What is Nuvectis Pharma, Inc.'s market cap?
- Nuvectis Pharma, Inc. (NVCT) has a market capitalization of $616.0M and trades on NASDAQ.
- Who are Nuvectis Pharma, Inc.'s competitors?
- Nuvectis Pharma, Inc.'s key competitors include Bristol-Myers Squibb, Pfizer, CNS Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Nuvectis Pharma, Inc. partner with?
- Nuvectis Pharma, Inc.'s notable partners include University of Edinburgh, CRT Pioneer Fund, Institute of Cancer Research.
- Where is Nuvectis Pharma, Inc. headquartered?
- Nuvectis Pharma, Inc. is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2022.